Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endocrinologist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Endocrinologist. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-002140-22 Sponsor Protocol Number: Vitality Start Date*: 2020-11-02
    Sponsor Name:Lars møller Pedersen
    Full Title: Gonadal dysfunction in male long-term survivors of malignant lymphoma
    Medical condition: Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10043335 Testicular hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003652-35 Sponsor Protocol Number: 300 Start Date*: 2006-02-02
    Sponsor Name:Barnsley Hospital NHS Foundation Trust
    Full Title: A randomised, double blind, placebo controlled study to assess the effect of testosterone treatment on arterial stiffness in patients with type 2 diabetes, peripheral vascular disease and hypogonad...
    Medical condition: Male Hypogonadism
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003678-82 Sponsor Protocol Number: CHDR0606 Start Date*: 2007-07-10
    Sponsor Name:Centre for Human Drug Research
    Full Title: Pharmacokinetics and effects of oral clonidine in children with suspected Growth Hormone deficiency
    Medical condition: Clonidine is studied in the paediatric population, more specific children with short stature. It is used as a diagnostic tool to establish Growth Hormone reserve in routine practice.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10005573 Blood growth hormone decreased LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005344-30 Sponsor Protocol Number: TETRA-pilot Start Date*: 2022-06-29
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: TETRA-pilot: Testosterone in transgender women after vaginoplasty: a dose-finding and feasibility pilot study
    Medical condition: Low testosterone levels in transgender women who underwent a vaginoplasty. We will investigate the serum testosterone levels at different doses of testosteron gel and if there are side effects.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002991-40 Sponsor Protocol Number: A6281269 Start Date*: 2015-04-01
    Sponsor Name:Pfizer Inc
    Full Title: Evolution of Growth Rate in Children Suffering From a Disease Associated With Growth Retardation and Treated by Genotonorm. A Pilot Study
    Medical condition: Growth Disorders, Growth Retardation
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004903-15 Sponsor Protocol Number: 2020-004903-15 Start Date*: 2022-04-20
    Sponsor Name:University of Alabama at Birmingham
    Full Title: Denosumab (DMAB) Discontinuation and Switching Study in Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
    Medical condition: Glucocorticoid-Induced Osteoporosis (GIOP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001845-15 Sponsor Protocol Number: TINCRBEL_study Start Date*: 2018-07-13
    Sponsor Name:Academic medical centre, department of internal medicine
    Full Title: EvaluaTion of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study (TINCRBEL study)
    Medical condition: Chronic intestinal failuyre (IF) is caused by large surgical bowel resection, severe motility, or absorption diseorders. These patientds require partial or total parenteral nutrition (PN and TPN, r...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002371-18 Sponsor Protocol Number: I8B-MC-ITSB Start Date*: 2019-03-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-PEDS
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) AT (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004876-37 Sponsor Protocol Number: PL37-C03-2013 Start Date*: 2014-03-31
    Sponsor Name:Pharmaleads SA
    Full Title: A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pa...
    Medical condition: Neuropathic pain develops as a result of damage to, or dysfunction of, the system that normally signals pain. It may arise from a heterogeneous group of disorders that affect the peripheral and cen...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002992-17 Sponsor Protocol Number: A6281271 Start Date*: 2015-05-14
    Sponsor Name:Pfizer, Inc.
    Full Title: EVOLUTION OF GROWTH RATE IN CHILDREN WITH GROWTH RETARDATION RELATED TO LONG-TERM GLUCOCORTICOSTEROID THERAPY AND TREATED BY GENOTONORM®
    Medical condition: Growth retardation related to long-term glucocorticoid therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10053759 Growth retardation PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004493-42 Sponsor Protocol Number: L-CP07-167 Start Date*: 2014-12-03
    Sponsor Name:Abbvie previously known as Abbott
    Full Title: A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children with Central Precocious Puberty
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004860 10073186 Central precocious puberty LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004494-16 Sponsor Protocol Number: L-CP07-177 Start Date*: 2014-12-03
    Sponsor Name:Abbvie previously known as Abbott
    Full Title: A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children with Central Precocious Puberty
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004860 10073186 Central precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003963-31 Sponsor Protocol Number: BEGAMI Start Date*: 2007-11-19
    Sponsor Name:Karolinska Institutet
    Full Title: A three months, double-blind, randomized, parallell-group study evaluating the efficacy of sitagliptin (Januvia®) versus placebo on beta-cell function in patients with newly detected glucose abnorm...
    Medical condition: Patients with acute myocardial infarction or unstable angina pectoris and newly detected impaired glucose tolerance or type 2 diabetes (without any previous pharmacological glucose-lowering treatment)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001233-27 Sponsor Protocol Number: PI2016_843_0008 Start Date*: 2016-11-03
    Sponsor Name:CHU Amiens Picardie
    Full Title: Efficacity and safety of metformin extended release (XR) in diabetic patients with CKD in stages 1 to 3 (METXR/CKD)
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013090-18 Sponsor Protocol Number: NN2211-3619 Start Date*: 2012-02-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 52-Week Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Multinational Exploratory Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Evaluate The...
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001867-35 Sponsor Protocol Number: NNCIT-02 Start Date*: 2019-04-24
    Sponsor Name:TikoMed AB
    Full Title: Open, Randomized, Active Comparator-controlled, Multi-Center Study to Evaluate Safety and Efficacy of IBsolvMIR® in Islet Transplantation
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004506-64 Sponsor Protocol Number: 17000139BLC3002 Start Date*: 2023-01-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG...
    Medical condition: BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) PT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006794-37 Sponsor Protocol Number: VRDN-001-101 Start Date*: 2022-08-03
    Sponsor Name:Viridian Therapeutics, Inc.
    Full Title: A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and sub...
    Medical condition: Thyroid eye disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10015919 - Eye disorders 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002620-36 Sponsor Protocol Number: 17000139BLC3001 Start Date*: 2021-05-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma...
    Medical condition: Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Completed) PT (Ongoing) AT (Ongoing) PL (Completed) BE (Ongoing) HU (Ongoing) GR (Ongoing) CZ (Trial now transitioned) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020437-12 Sponsor Protocol Number: DT-DP-D2b Start Date*: Information not available in EudraCT
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A multicentric, double blind, randomized, comparative Phase II b study of the efficacy of a wound healing solution in patients with diabetic foot ulcer
    Medical condition: diabetic foot ulcer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA